Here, we reported that the tracking of MYC expression in CTCs was feasible and it might be of interest in BC patients, in agreement with Reinhardt and colleagues, who described high MYC expression in CTCs’ differential phenotypes in BC [49]. This evidence concerns the gene MYC and breast cancer.